D2C nutrition brand BeastLife raises Rs 20 crore at Rs 320 crore valuation from GVFL and Equentis

The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years

Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027

As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million

FDA okays Eli Lilly’s new weight-loss pill, expanding options for millions

The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants

Lupin completes acquisition of VISUfarma

The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe

Orca Bio’s Orca-T FDA review extended to July 2026

Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal

The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions

Rusan unveils APOSAN 3ml multi-dose pen

The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes

Merck completes acquisition of JSR Life Sciences’ chromatography business

Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing

Bristol Myers Squibb expands groundbreaking program to close faps in multiple myeloma care

The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners

Investigational therapy efzimfotase alfa shows promising Phase III results in rare bone disease

Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume